在轻度急性缺血性中风 (TiMIS) 中,提罗菲班与连续的双重抗血小板治疗:多中心,随机对照试验的协议
Jiaping Xu1, Hao Peng2,3, Yafang Zhu1
1Department of Neurology and Suzhou Clinical Research Center of Neurological Disease, Second Affiliated Hospital of Soochow University, Suzhou, China.
Annals of medicine
|March 16, 2026
概括
这项研究调查了静脉注射蒂罗菲班加双抗血小板治疗 (DAPT) 是否改善了轻度急性缺血性中风 (AIS) 患者的结果. 结果将为未来针对AIS的抗血栓策略提供信息.
科学领域:
- 神经学 神经学
- 心血管医学 心血管医学
- 临床试验 临床试验
背景情况:
- 接受双重抗血小板治疗 (DAPT) 的轻度急性缺血性中风 (AIS) 患者仍然面临神经系统恶化的风险和不良结果.
- 静脉注射的铁洛菲班,一种糖蛋白IIb/IIIa抑制剂,可能会减轻这些风险,但对轻度AIS的证据有限.
研究的目的:
- 为了评估静脉注射的蒂罗菲班,然后是DAPT,与单独的DAPT相比,在轻度非心血管血栓性AIS患者中,在90天后改善了优良的功能结果.
- 评估这种联合治疗策略的疗效和安全性.
主要方法:
- 未来的多中心随机受控试验 (TiMIS) 招募688名轻度AIS患者在发病后48小时内.
- 患者被随机分配1:1接受静脉注射蒂罗菲班48小时,随后接受DAPT或单独DAPT.
- 主要结局:在90天内,修改的兰金度量表 (mRS) 得分为0-1的患者比例.
主要成果:
- 关于90天后功能性结果的初级结果数据正在等待.
- 二次结果包括早期的神经系统恶化,中风发生率和安全事件.
结论:
- 蒂米斯试验将提供关键证据,证明早期静脉注射蒂罗菲班与DAPT结合治疗轻度AIS的有效性.
- 这些发现可能会指导未来对这种患者群体的抗血栓治疗策略.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Venous Thrombosis III: Interprofessional Care
453
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
453
Coronary Artery Disease V: Interprofessional Care
363
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
363
Acute Coronary Syndrome IV: Interprofessional Care
391
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
391
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
618
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
618


